Clinical Trial

Influence Mechanism of Tumor Microenvironment Changes on Neoadjuvant Therapy for Esophageal Squamous Cell Carcinoma

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated November 25, 2024 (before its estimated June 30, 2025 completion). Its status may not reflect the trial's current state.
Summary
To evaluate the predictive value and mechanism of inflammatory factors in peripheral blood on the prognosis of patients, and to explore the influencing factors of inflammation and tumor microenvironment on the efficacy of neoadjuvant chemotherapy combined with immunotherapy for esophageal cancer. To explore the predictors of neoadjuvant therapy in patients with esophageal squamous cell carcinoma.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2023-06-07; most recent amendment 2024-11-20.
Trial Details
NCT Number NCT05894369
Lead Sponsor Renmin Hospital of Wuhan University
Conditions Esophageal Cancer
Enrollment 10 participants
Start Date 2023-05-04
Primary Completion 2025-06-30 (estimated)
Study Completion 2025-12-30 (estimated)
Updated on ClinicalTrials.gov 2024-11-25